Clinical TrialMay 26, 2026, 08:01 AM
BioVie Fully Enrolls Long COVID Phase 2 Trial; Data Expected Late Summer 2026
AI Summary
BioVie Inc. announced the full enrollment of its ADDRESS-LC Phase 2 trial for bezisterim, targeting neurological symptoms of Long COVID. The study, fully funded by a $13.13 million grant from the U.S. Department of War, enrolled approximately 200 patients. Topline data from this trial is anticipated in late summer 2026. Bezisterim is also being investigated for Parkinson's disease, with SUNRISE-PD study results expected in Q3 2026, and for Alzheimer's disease.
Key Highlights
- BioVie fully enrolled its ADDRESS-LC Phase 2 trial for bezisterim in Long COVID.
- Topline data from the Long COVID trial is expected late summer 2026.
- The Phase 2 study is fully funded by a $13.13 million grant from the U.S. Department of War.
- Approximately 200 patients were enrolled in the ADDRESS-LC trial.
- Bezisterim is also in a Parkinson's disease study (SUNRISE-PD) with 60 patients.
- Topline results for the Parkinson's SUNRISE-PD study are expected in Q3 2026.
- Bezisterim is an investigational oral drug targeting inflammation and insulin sensitivity.
Price Impact
More from BIVI